The deal priced below last closing price of $11.21. H.C. Wainwright is acting as sole book running manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GYRE:
- Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
- Gyre Therapeutics Achieves Key Milestone in Phase 3 Trial
- Gyre Therapeutics announces Hydronidone trial met primary endpoint
- Gyre Therapeutics announces common stock offering, no amount given
- Gyre Therapeutics Reports Q1 2025 Financial Results